ModerateCaution
Berberine
Berberine can lower glucose and may add to possible MOTS-c metabolic effects.
Recommendation: Avoid combining in diabetes or hypoglycemia risk without clinician monitoring.
MOTS-c
Peptide ·Insufficient evidence ·Reviewed May 2026
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region and studied for metabolic stress signaling. It is not FDA-approved, and human therapeutic data remain early and limited. Claims for fat loss, longevity, or exercise mimicry rely mainly on animal and mechanistic evidence.
What it's good for
What to watch for
- Unknown long-term safety
- Injection-site reaction
- Possible glucose lowering
- Diabetes medications or hypoglycemia risk without clinician review
- Pregnancy and breastfeeding
The bottom line
Evidence rating insufficient. Most-documented uses: metabolic homeostasis research, exercise and aging biology, insulin-sensitivity animal data. 3 sources indexed (2015–2024), with 3 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
MOTS-c can act as a mitochondrial-to-nuclear stress signal and has been linked to folate-AICAR-AMPK pathways, glucose uptake, insulin sensitivity, and exercise adaptation in preclinical studies. Human circulating MOTS-c appears responsive to exercise and metabolic state, but exogenous supplementation has not been validated as safe or effective. Glucose effects are the main practical monitoring concern.1,2
Class
Mitochondrial-derived metabolic peptide
Found in food
None as a dietary supplement
Low-status signs
No recognized dietary deficiency state exists for this peptide
Dosing
Dosing & protocol.
Common range
No FDA-approved human dose; research dosing is protocol-specific
Recommended form
Not recommended for human use; research reagent only
Peptides are generally not reliably orally bioavailable unless a specific studied oral formulation is used. Human use of research-grade products is not appropriate.
Forms
Forms & what to buy.
Ranked by evidence and value.
Laboratory Research Reagent Recommended
Nonhuman metabolic research only. Not for human injection.
Injectable Research MOTS-c
Systemic human use is not approved. Sterility and glycemic effects are uncertain.
Cost
What it actually costs.
Real-world pricing across three quality tiers. Assumes Laboratory Research Reagent.
BudgetBest value
$60 /mo
$2.00 per dose
Mid
$180 /mo
$6.00 per dose
Premium
$450 /mo
$15.00 per dose
Research-market pricing is not a dosing recommendation; human use is not FDA-approved unless specifically stated. Updated 2026-06-04.
Goals
Goal-based dosing.
Metabolic Research
Dose: Protocol-specific only1,3
Timing: Study protocol only
Animal results do not define human dosing.
Fat Loss or Longevity
Dose: No FDA-approved dose
Timing: Not applicable
Claims exceed evidence.
Insulin Resistance
Dose: No approved dose3
Timing: Not applicable
Use established metabolic treatments.
Lab work
Markers to track.
What to test, the optimal window inside the conventional range, and how long a response takes.
Fasting Glucose Glucose
May improve glucose handling in animal models; human effect is unproven.3
Optimal
70–90 mg/dL
Conventional
70–99 mg/dL
Responds in
Baseline and 4-12 weeks in any supervised study
70optimal99
Monitor closely in diabetes or hypoglycemia risk.
HbA1cFasting insulin
Why people use it
Symptoms it's matched to.
Where this appears in the symptom-to-supplement map, ranked by relevance.
Insulin resistance
14% relevance
Animal data support metabolic plausibility but not treatment use.3,1
MetabolicEmerging evidenceAvoid outside research
Use standard diabetes prevention and treatment.
Low exercise tolerance
8% relevance
Exercise-mimetic claims are preclinical.2
EnergyInsufficient evidenceAvoid
Evaluate anemia, cardiopulmonary disease, sleep, and conditioning.
Low energy
5% relevance
Mitochondrial claims are speculative for nonspecific fatigue.1,2
EnergyInsufficient evidenceAvoid
Check common medical causes.
Safety
Full safety detail.
Side effects
- Unknown long-term safety
- Injection-site reaction
- Possible glucose lowering
- Headache
- Fatigue
- Product contamination risk
Contraindications
- Diabetes medications or hypoglycemia risk without clinician review
- Pregnancy and breastfeeding
- Active cancer without oncology clearance
- Any unsupervised human use1
- Research-grade injectable products
Interactions
Interaction records.
ModerateCaution
Alpha-Lipoic Acid
Alpha-lipoic acid can improve insulin sensitivity and may increase hypoglycemia risk in a metabolic peptide stack.
Recommendation: Monitor glucose only in supervised settings; avoid self-use.
InfoCaution
Creatine
Creatine may improve training output and confound interpretation of MOTS-c exercise claims.
Recommendation: Change one performance intervention at a time.
Sources
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
1- 1The correlation between mitochondrial derived peptide (MDP) and metabolic states: a systematic review and meta-analysisNeeds sourceNo linkLi H et al. · Frontiers in Endocrinology · 2024
MOTS-c levels correlate with metabolic phenotypes
Mechanistic & preclinical
2- 2MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasisNeeds sourceNo linkReynolds JC et al. · Nature Communications · 2021
MOTS-c improved physical performance in mice
- 3The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistanceNeeds sourceNo linkLee C et al. · Cell Metabolism · 2015
Improved insulin sensitivity in models
Keep exploring
Deep dives & adjacent profiles.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
MOTS-c in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.